Article Sidebar

article details
Date Published: 28/04/2025
Online Published: 28/04/2025
Abstract Views: 155
Views article details: 58
DOI: https://doi.org/10.54804/yhthvb.2.2025.409
Issue
No. 2 (2025)
Section
Articles
How to Cite
Mai, T. B. (2025). Treatment of pancreatic duct - related disorders diseases - preliminary outcomes of endoscopic retrograde cholangiopancreatography with pancreatic stent placement in the. Journal of Disaster Medicine and Burn Injuries, 2, 83-91. https://doi.org/10.54804/yhthvb.2.2025.409

Treatment of pancreatic duct - related disorders diseases - preliminary outcomes of endoscopic retrograde cholangiopancreatography with pancreatic stent placement in the

Mai Thanh Binh1,
1 108 Military Central Hospital

Main Article Content

Abstract

Objective: To provide a preliminary assessment of the efficacy and safety of endoscopic retrograde cholangiopancreatography (ERCP) with pancreatic duct intervention for the treatment of pancreatic duct diseases at 108 Military Central Hospital.
Subjects and Methods: A total of 44 patients with pancreatic duct dilation or pancreatic duct lesions underwent ERCP with pancreatic duct stenting at 108 Military Central Hospital from January 2021 to March 2024.
Results: All patients received plastic stents, with 40 patients receiving one stent and 4 patients receiving two stents. The mean procedure time was 49.4 ± 19.5 minutes, and the average hospital stay was 14.2 ± 9.5 days. The pre-procedure abdominal pain rate was 68.2%, which decreased to 54.5% post-procedure and further dropped to 27.3% at discharge. The pre-procedure fever rate was 20.5%, decreasing to 9.1% post-procedure. Pancreatic enzyme levels (amylase and lipase) showed a decreasing trend after pancreatic stent placement, but the changes were not statistically significant. Adverse events and complications were observed in 13 patients (29.5%), with acute pancreatitis being the most common complication (7/13 patients).
Conclusion: ERCP with pancreatic duct stenting demonstrates a supportive role in managing conditions causing pancreatic duct dilation. It should be considered, particularly for benign diseases such as chronic pancreatitis and pancreatic pseudocysts communicating with the pancreatic duct.

Article Details

Keywords

Pancreatic diseases, endoscopic retrograde cholangiopancreatography, pancreatic duct stent placement

References

1. Thái Doãn Kỳ và cộng sự (2023). Đánh giá hiệu quả và an toàn của phương pháp nội soi mật tụy ngược dòng điều trị sỏi đường mật tại Bệnh viện Trung ương Quân đội 108. Tạp chí Y dược Lâm sàng 108, 2023. 18.
2. Trần Duy Hưng và cộng sự (2022). Chẩn đoán và điều trị viêm tụy cấp do tụy đôi bằng đặt stent ống tụy qua nội soi mật tụy ngược dòng: nhân 1 ca lâm sàng. Tạp chí Nghiên cứu Y học, 2022. 160: tr. 330-334.
3. PancreasGroup.org, C., Pancreatic surgery outcomes: multicentre prospective snapshot study in 67 countries. Br J Surg, 2024. 111(1).
4. Phillip, V., et al., Pancreatic stenting to prevent post-ERCP pancreatitis: a randomized multicenter trial. Endosc Int Open, 2019. 7(7): p. E860-E868.
5. Sofuni, A., et al., Endoscopic pancreatic duct stents reduce the incidence of post-endoscopic retrograde cholangiopancreatography pancreatitis in high-risk patients. Clin Gastroenterol Hepatol, 2011. 9(10): p. 851-8; quiz e110.
6. Sung, H., et al., Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin, 2021. 71(3): p. 209-249.
7. Testoni, P.A., Endoscopic pancreatic duct stent placement for inflammatory pancreatic diseases. World J Gastroenterol, 2007. 13(45): p. 5971-8.
8. Wilcox, C.M., et al., Chronic pancreatitis pain pattern and severity are independent of abdominal imaging findings. Clin Gastroenterol Hepatol, 2015. 13(3): p. 552-60; quiz e28-9.
9. Zolotarevsky, E., et al., Prophylactic 5-Fr pancreatic duct stents are superior to 3-Fr stents: a randomized controlled trial. Endoscopy, 2011. 43(4): p. 325-30.